Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Event, Webcast

Capstan Therapeutics to Participate in Upcoming Industry Conferences


Capstan Therapeutics, Inc., a biotechnology company dedicated to advancing in vivo reprogramming of cells through targeted lipid nanoparticles, today announced that Capstan management will participate in the following upcoming industry conferences:

Jefferies Cell and Genetic Medicine Summit
Date: Tuesday, September 26, 2023
Time: 12:45 p.m. EDT
Location: New York, NY

Chief Scientific Officer and Executive Vice President of R&D, Adrian Bot, M.D., Ph.D., will participate in a virtual panel discussion titled "CAR T Beyond Cancer."

2023 Cell & Gene Meeting on the Mesa
Date: Tuesday, October 10, 2023
Time: 9:30 a.m. PT
Location: Rentschler ATMP Ballroom at the Park Hyatt Aviara Resort in Carlsbad, CA

Chief Scientific Officer and Executive Vice President of R&D, Adrian Bot, M.D., Ph.D., will give a company presentation.

BMO Biopharma Spotlight Series: (R)Evolution of RNA Therapies
Date: Tuesday, October 10, 2023
Location: Virtual

Company management will participate in 1:1 investor meetings.

Leerink Partners Biopharma Private Company Connect
Date: Wednesday, October 25 ? Thursday, October 26, 2023
Location: Virtual

Company management will participate in 1:1 investor meetings.

About Capstan (www.capstantx.com)

Capstan Therapeutics is a biotechnology company dedicated to advancing in vivo cell reprogramming. The core platform technology comprises proprietary targeted lipid nanoparticles (tLNPs) that are composed of LNPs conjugated with a recombinant protein binder, such as a monoclonal antibody. tLNPs are designed to deliver payloads, including mRNA or gene editing tools, capable of reprogramming specific cell types in vivo. The platform technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including oncology, autoimmune disorders, fibrosis, and monogenic blood disorders. For more information, please visit www.capstantx.com and follow us on LinkedIn.


These press releases may also interest you

at 07:05
Tectonic Therapeutic, Inc. a biotechnology company transforming the discovery of novel GPCR-targeted therapies (G-Protein Coupled Receptors), today announced it completed dosing of the first human cohort in its Fc-relaxin fusion program targeting the...

at 07:05
Rallybio Corporation today announced preliminary data from the completed multiple dose cohort of the Phase 1 safety and pharmacokinetics (PK) study for RLYB212, an anti-HPA-1a monoclonal antibody for the prevention of fetal and neonatal alloimmune...

at 07:05
Vedanta Biosciences, a clinical-stage company developing a potential new category of oral therapies based on defined bacterial consortia, today announced that the Opposition Division of the European Patent Office (EPO) has fully upheld Vedanta's...

at 07:05
Precision BioSciences, Inc. , an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today...

at 07:01
HelixVMtm, a virtual healthcare marketplace, showcases its ability to significantly increase physician capacity, revolutionizing the way healthcare is delivered. The pioneering marketplace platform demonstrated the capability to streamline...

at 07:00
The Lung Health Foundation is thrilled to announce that ProResp, a steadfast partner for 17 years, has generously pledged a matching gift of $15,000 this Giving Tuesday. ProResp has consistently demonstrated its commitment to advancing respiratory...



News published on and distributed by: